Penfigoide bolhoso


Principais artigos

Cotell S, Robinson ND, Chan LS. Autoimmune blistering skin diseases. Am J Emerg Med. 2000;18:288-299. Resumo

Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010;(10):CD002292.Texto completo  Resumo

Kirtschig G, Khumalo NP. Management of bullous pemphigoid: recommendations for immunomodulatory treatments. Am J Clin Dermatol. 2004;5:319-26. Resumo

Artigos de referência

1. Liu Z. Are anti-BP180 IgG1 or IgG4 autoantibodies pathogenic? J Invest Dermatol. 2002;119:989-990.

2. Yeh SW, Ahmed B, Sami N, et al. Blistering disorders: diagnosis and treatment. Dermatol Ther. 2003;16:214-223. Resumo

3. Walsh SR, Hogg D, Mydlarski PR. Bullous pemphigoid: From bench to bedside. Drugs. 2005;65:905-926. Resumo

4. Williams DM. Vesiculo-bullous mucocutaneous disease: Benign mucous membrane and bullous pemphigoid. J Oral Pathol Med. 1990;19:16-23. Resumo

5. Korman NJ. Bullous pemphigoid. The latest in diagnosis, prognosis, and therapy. Arch Dermatol. 1998;134:1137-1141. Resumo

6. Jung M, Kippes W, Messer G, et al. Increased risk of bullous pemphigoid in male and very old patients: A population-based study on incidence. J Am Acad Dermatol. 1999;41:266-268. Resumo

7. Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris - incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180.Texto completo  Resumo

8. Joly P, Baricault S, Sparsa A, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol. 2012 Aug;132(8):1998-2004.Texto completo  Resumo

9. Ujiie H, Iwata H, Yamagami J, et al. Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita). J Dermatol. 2019 Dec;46(12):1102-35.Texto completo  Resumo

10. Kridin K. Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations. Immunol Res. 2018 Feb;66(1):6-17. Resumo

11. Chimanovitch I, Hamm H, Georgi M, et al. Bullous pemphigoid of childhood: Autoantibodies target the same epitopes within the NC16A domain of BP180 as autoantibodies in bullous pemphigoid of adulthood. Arch Dermatol. 2000;136:527-532. Resumo

12. Fisler RE, Saeb M, Liang MG, et al. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature. Am J Dermatopathol. 2003;25:183-189. Resumo

13. Wong SN, Chua SH. Spectrum of subepidermal immunobullous disorders seen at the national skin centre, Singapore: a 2-year review. Br J Dermatol. 2002;147:476-480. Resumo

14. Gudi VS, White MI, Cruickshank N, et al. Annual incidence and mortality of bullous pemphigoid in the Grampian region of north-east Scotland. Br J Dermatol. 2005;153:424-427. Resumo

15. Schmidt E, Zillikens D. Autoimmune and inherited subepidermal blistering diseases: Advances in the clinic and the laboratory. Adv Dermatol. 2000;16:113-157. Resumo

16. Dilling A, Rose C, Hashimoto T, et al. Anti-p200 pemphigoid: A novel autoimmune subepidermal blistering disease. J Dermatol. 2007;34:1-8. Resumo

17. Giudice GJ, Emery DJ, Zelickson BD, et al. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol. 1993;151:5742-5750. Resumo

18. Haase C, Budinger L, Borradori L, et al. Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2. J Invest Dermatol. 1998;110:282-286. Resumo

19. Schmidt E, Brocker EB, Zillikens D. New aspects on the pathogenesis of bullous pemphigoid. Hautarzt. 2000;51:637-645. Resumo

20. Gammon WR, Merritt CC, Lewis DM, et al. An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement. J Invest Dermatol. 1982;78:285-290. Resumo

21. Sitaru C, Schmidt E, Petermann S, et al. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol. 2002;118:664-671. Resumo

22. Liu Z, Diaz LA, Troy JL, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest. 1993;92:2480-2488. Resumo

23. Hofmann S, Thoma-Uszynski S, Hunziker T, et al. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol. 2002;119:1065-1073. Resumo

24. Wakugawa M, Nakamura K, Hino H, et al. Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia. Br J Dermatol. 2000;143:112-116. Resumo

25. Joly P, Benichou J, Lok C, et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol. 2005;141:691-698. Resumo

26. Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol. 2002;138:903-908. Resumo

27. Delgado JC, Turbay D, Yunis EJ, et al. A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci USA. 1996;93:8569-8571. Resumo

28. Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015 Apr;172(4):867-77. Resumo

29. Lamb PM, Abell E, Tharp M, et al. Prodromal bullous pemphigoid. Int J Dermatol. 2006;45:209-214. Resumo

30. Santi CG, Gripp AC, Roselino AM, et al. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology. An Bras Dermatol. 2019 Apr;94(2 suppl 1):33-47.Texto completo  Resumo

31. Di Zenzo G, Calabresi V, Grosso F, et al. The intracellular and extracellular domains of BP180 antigen comprise novel epitopes targeted by pemphigoid gestationis autoantibodies. J Invest Dermatol. 2007;127:864-873. Resumo

32. Labib RS, Anhalt GJ, Patel HP, et al. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol. 1986;136:1231-1235. Resumo

33. De Jong MC, Bruins S, Heeres K, et al. Bullous pemphigoid and epidermolysis bullosa acquisita. differentiation by fluorescence overlay antigen mapping. Arch Dermatol. 1996;132:151-157. Resumo

34. Daneshpazhooh M, Shahdi M, Aghaeepoor M, et al. A comparative study of antibody titers of blister fluid and serum in patients with subepidermal immunobullous diseases. Int J Dermatol. 2004;43:348-51. Resumo

35. Cotell S, Robinson ND, Chan LS. Autoimmune blistering skin diseases. Am J Emerg Med. 2000;18:288-299. Resumo

36. Verdolini R, Cerio R. Autoimmune subepidermal bullous skin diseases: the impact of recent findings for the dermatopathologist. Virchows Arch. 2003;443:184-193. Resumo

37. Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010;(10):CD002292.Texto completo  Resumo

38. Venning VA, Taghipour K, Mohd Mustapa MF, et al. British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012. Br J Dermatol. 2012;167:1200-14.Texto completo  Resumo

39. Bekier E, Maslinski C. Antihistaminic action of nicotinamide. Agents Actions. 1974;4:196. Resumo

40. Kirtschig G, Khumalo NP. Management of bullous pemphigoid: recommendations for immunomodulatory treatments. Am J Clin Dermatol. 2004;5:319-26. Resumo

41. Bernard P, Charneux J. Bullous pemphigoid: a review [in French]. Ann Dermatol Venereol. 2011;138:173-181. Resumo

42. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol. 2007;143:1536-1542. Resumo

43. Wetter DA, Davis MD, Yiannias JA, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc. 2005;80:41-47. Resumo

44. Engineer L, Ahmed AR. Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data. J Am Acad Dermatol. 2001;44:83-88. Resumo

45. Schulze J, Bader P, Henke U, et al. Severe bullous pemphigoid in an infant - successful treatment with rituximab. Pediatr Dermatol. 2008;25:462-465. Resumo

46. Schmidt E, Bröcker EB, Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol. 2008;34:56-64. Resumo

47. Reguiaï Z, Tchen T, Perceau G, et al. Efficacy of rituximab in a case of refractory bullous pemphigoid [in French]. Ann Dermatol Venereol. 2009;136:431-434. Resumo

48. Peterson JD, Chan LS. Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: a comprehensive survey of 71 consecutive patients from the initial use to 2007. Ther Clin Risk Manag. 2009;5:1-7.Texto completo  Resumo

49. Colbert RL, Allen DM, Eastwood D, et al. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol. 2004;122:1091-5. Resumo

50. Bystryn JC, Rudolph JL. Why is the mortality of bullous pemphigoid greater in Europe than in the US? J Invest Dermatol. 2005;124:xx-xxi. Resumo

51. Parker SR, Dyson S, Brisman S, et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol. 2008;59:582-588. Resumo

52. Roujeau JC, Lok C, Bastuji-Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol. 1998;134:465-469.Texto completo  Resumo

53. Summey BT, Yosipovitch G. Glucocorticoid-induced bone loss in dermatologic patients: an update. Arch Dermatol. 2006;142:82-90. Resumo

54. Gourlay M, Franceschini N, Sheyn Y. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures. Clin Rheumatol. 2007;26:144-153. Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal